Institutional investors and medical innovation
Omer Unsal, Blake Rayfield
Research Overview
In this research paper, we investigate if institutional investors influence corporate innovation in the US pharmaceutical industry. We hand collect unique datasets from the Food and Drug Administration (FDA), including drug patents, drug approvals, medical device approvals, and Phase I-II-III drugs under clinical testing. We find that higher institutional ownership has a positive, causal effect on firm innovation. We document that institutional ownership increases the number of FDA approved products.
Plain-English Summary
Institutional investors can influence innovation in the pharmaceutical industry, where medical products require long and uncertain development cycles. The study finds a positive relationship between institutional ownership and medical innovation.